News & Events
FDA approves new lung transplant
- October 4, 2019
- Posted by: Wiley M. Wagner
- Category: Science
Modern transplantology keeps many really important points from the attention of specialists and end donors – one of the biggest problems in this context is the determination of a potentially suitable organ for transplantation. It is for this purpose that researchers from the United States today introduced a new system called the Xvivo Perfusion System, whose purpose is to evaluate, analyze and even slightly improve the condition of donor organs that are potentially considered for further use – and this means that in theory will become more than the proportion of organs suitable for transplantation.
It is worth noting that so far this technology is designed to analyze and evaluate donor lungs, since this organ is the most problematic in the statistics of its transplantation – about 15% of the total world number of donor organs are really suitable. It became known that at this point in time the technology has become officially sanctioned and authorized by the Federal Commission for the Control of Food and Drug Administration of the United States, thereby gradually becoming one of the most tested and multifunctional options for the analysis of donor organs.
Thus, the new technology has a number of parameters and capabilities that clearly distinguish it from similar assessment systems, not to mention determining the ultimate organ fitness limit – for example, the Xvivo Perfusion System has the ability to autonomously pump the lungs up to five hours and keep them active so that they can be studied in more detail before surgery.
If everything goes according to the initial plan of specialists, then in the very near future a really stunning result can be expected – both in terms of increasing the total global volume of organs suitable for transplantation, and in the context of reducing the time required to evaluate and analyze the donor organ, which may really save even more lives.